Business Context and Reporting Period
This summary covers the Form 10-K for PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc., which later became Revvity). The report covers the fiscal year ended December 30, 2001. PerkinElmer is a global high-technology company operating in three continuing segments: Life Sciences, Optoelectronics, and Analytical Instruments. The company operates in over 125 countries and is a component of the S&P 500 Index.
Key Financial Metrics
| Metric | 2001 (in millions) | 2000 (in millions) |
|---|---|---|
| Total Sales (Continuing Ops) | $1,330.1 | $1,335.5 |
| Operating Income (Continuing Ops) | $63.9 | $132.7 |
| Net Income | $34.5 | $90.5 |
| Net Income from Continuing Ops | $(0.6) | $59.3 |
| Net Income from Discontinued Ops | $32.8 | $26.8 |
| Cash Flow from Operating Activities | $123.3 | $145.5 |
| Total Assets | $2,919.1 | $2,188.3 |
| Total Debt (Short + Long Term) | $723.9 | $766.4 |
| Stockholders' Equity | $1,363.6 | $728.4 |
Material Changes vs. Prior Period
- Revenue Stability: Total sales from continuing operations remained relatively flat, decreasing slightly by $5.4 million (less than 1%) compared to 2000. This stability was driven by approximately $102 million in incremental revenue from the acquisitions of Packard BioScience and NEN Life Sciences, which offset a $74 million decline from divested businesses, a $26 million negative foreign exchange impact, and an $8 million organic decline.
- Profitability Decline: Operating income from continuing operations dropped significantly by 52% to $63.9 million. This was primarily due to nonrecurring charges totaling $81.2 million, including $69.0 million in in-process research and development (IPR&D) charges related to the Packard acquisition, restructuring costs, and amortization of intangibles.
- Segment Performance:
- Life Sciences: Sales increased 56% to $346.1 million due to acquisitions and organic growth, though it reported an operating loss of $46.0 million due to acquisition-related charges.
- Optoelectronics: Sales declined 16% to $415.7 million due to weakness in telecom and semiconductor markets. Operating profit fell 53% to $45.8 million.
- Analytical Instruments: Sales decreased 8% to $568.2 million, but operating profit increased 38% to $78.4 million, aided by gains on the disposition of the IRAS business.
- Discontinued Operations: The company classified Fluid Sciences and Security and Detection Systems as discontinued operations. These units contributed $32.8 million to net income in 2001.
Guidance, Outlook, and Risks
- Acquisitions and Divestitures: The company completed the acquisition of Packard BioScience for approximately $762 million (stock and debt assumption) in November 2001. It also sold the Instruments for Research and Applied Science (IRAS) and Voltarc Technologies businesses in Q4 2001. Plans to sell Fluid Sciences and Security and Detection Systems were approved, with the latter expected to finalize in H1 2002.
- Capital Expenditures: CapEx increased to $88.7 million in 2001, driven by a new headquarters for Analytical Instruments and telecom manufacturing expansion. The company estimates 2002 CapEx at approximately $60 million.
- Liquidity and Debt: The company maintains $370 million in unsecured credit lines. Long-term debt includes $483 million in zero-coupon senior convertible debentures (due 2020) and $115 million in unsecured notes (due 2005). The company expects operations to generate sufficient cash for expenses and interest payments but may require external funds for large acquisitions or debt refinancing.
- Risks: Key risks include cyclical downturns in end-markets (telecom, semiconductor), the inability to successfully integrate acquired businesses, foreign exchange volatility (56% of sales are international), and potential environmental liabilities (accrued at $6.9 million).
Investor Verification Checklist
- Nonrecurring Charges: Verify the impact of the $69 million IPR&D charge and other restructuring costs on the reported loss from continuing operations versus the adjusted operating profit of $191.7 million.
- Discontinued Operations: Confirm the status and expected proceeds from the sale of the Security and Detection Systems and Fluid Sciences businesses.
- Debt Maturity: Review the repayment schedule for the $118 million Packard debt (reclassified to short-term) and the $115 million notes due in 2005.
- Intangible Assets: Assess the $1.5 billion in net intangible assets (including $1.1 billion in goodwill) and the implications of the new SFAS No. 142 standard on goodwill impairment testing.
- Segment Mix: Monitor the shift in revenue concentration toward the Life Sciences segment following the Packard acquisition.